Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
People Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to Refocus on Cardiovascular CareDaiichi Sankyo2022-05-24 17:15:36People Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to
-
New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillationDaiichi Sankyo2021-04-26 09:44:48New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with
-
First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® ▼ (bempedoic acid and ezetimibe) tablet approved in SwitzerlandDaiichi Sankyo2021-02-02 11:33:17First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with
-
Pooled analyses show NILEMDO®▼ significantly lowers cholesterol in different subgroups in Phase 3 data presented at AHA 2020Daiichi Sankyo2020-11-16 10:51:13Pooled analyses show NILEMDO®▼ significantly lowers cholesterol in different subgroups in Phase 3 data
-
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA (edoxaban) during routine clinical careDaiichi Sankyo2020-09-01 10:19:50New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and
-
NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during 2.5 years of treatmentDaiichi Sankyo2023-11-09 20:59:16NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during
-
ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights important clinical considerations for treating elderly patients with atrial fibrillationDaiichi Sankyo2023-11-09 20:59:05ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights
-
New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI® approved in EuropeDaiichi Sankyo2020-08-03 09:23:48New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI®
-
Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice for Elderly AF Patients with ComorbiditiesDaiichi Sankyo2020-08-03 09:24:40Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice
-
Bempedoic Acid Lowers LDL-Cholesterol without Adversely Impacting Glycaemic Control in Pooled Analyses of Phase 3 Trials Presented at the American Heart Association 2019 Scientific SessionsDaiichi Sankyo2020-08-03 09:25:37Bempedoic Acid Lowers LDL-Cholesterol without Adversely Impacting Glycaemic Control in Pooled Analyses of
